5.80 -0.05 (-0.85%)
ZGEN
Stock Details
Last Trade:5.80 Change:-0.05 (-0.85%) Prev Close:5.85 Open: 5.86 Days Range:5.72 – 5.88 52 Week Range: 3.44 - 7.31 Volume:116208 P/E: N/AEPS:-0.62
View AllRecent Alerts 03/18/10
Recent Alert on 02/11/10 at 4:15pm
ZymoGenetics, Inc. (ZGEN) Posts Q4 EPS of $0.19, Tops by 1c; Guides FY10 Revs Above Street
ZymoGenetics, Inc. (ZGEN) Posts Q4 EPS of $0.19, Tops by 1c; Guides FY10 Revs Above Street
ZymoGenetics, Inc. (NASDAQ: ZGEN) reports Q4 EPS of $0.19, 1 cents better than the analyst estimate of $0.18. Revenue for the quarter was $62.1 million, which compares to the estimate of $59.7 million. Sees FY10 loss $0.23 - $0.41, versus... Read More
Recent Alert on 02/11/10 at 4:15pm
ZymoGenetics, Inc. (ZGEN) Posts Q4 EPS of $0.19, Tops by 1c; Guides FY10 Revs Above Street
ZymoGenetics, Inc. (ZGEN) Posts Q4 EPS of $0.19, Tops by 1c; Guides FY10 Revs Above Street
Recent Alert on 02/11/10 at 4:15pm
ZymoGenetics, Inc. (ZGEN) Posts Q4 EPS of $0.19, Tops by 1c; Guides FY10 Revs Above Street
ZymoGenetics, Inc. (ZGEN) Posts Q4 EPS of $0.19, Tops by 1c; Guides FY10 Revs Above Street
Recent Alert on 02/02/10 at 7:44am
ZymoGenetics (ZGEN) Publishes Positive Results for Eight RECOTHROM Clinical Trials
ZymoGenetics (ZGEN) Publishes Positive Results for Eight RECOTHROM Clinical Trials
Recent Alert on 02/02/10 at 7:44am
ZymoGenetics (ZGEN) Publishes Positive Results for Eight RECOTHROM Clinical Trials
ZymoGenetics (ZGEN) Publishes Positive Results for Eight RECOTHROM Clinical Trials
View AllRecent Press Releases
No Recent Press Releases Available
View AllRecent SEC Filings
No Recent SEC Filings Available
View AllRecent Blog Posts
Blog Posts on 09/20/09 at 4:50pm
Spectrum Pharmaceuticals: Despite Share Offering, Still Cheap vs. Other Cancer Drugmakers
Spectrum Pharmaceuticals: Despite Share Offering, Still Cheap vs. Other Cancer Drugmakers